%0 Case Reports
%T Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient.
%A Onuki T
%A Morita E
%A Sakamoto N
%A Nagai Y
%A Sata M
%A Hagiwara K
%J Respirol Case Rep
%V 6
%N 6
%D Aug 2018
%M 30065841
暂无%R 10.1002/rcr2.334
%X Pembrolizumab is an immune checkpoint inhibitor that induces side effects called "immune-related adverse events" (irAEs). Various types of organs are affected by irAEs, although reports of upper gastrointestinal disorders are rare. Here, we report a case of extensive inflammatory pathologies in the oesophagus, stomach, duodenum, and jejunum after the administration of pembrolizumab for non-small cell lung cancer.